Aurinia Pharmaceuticals Inc. (AUPH) Financial Statements — Income, Balance Sheet, Cash Flow

Overview Financials Chart Business Summary Filings Ownership Valuation

Financial Statements — AUPH

Balance Sheet

(in millions USD)

Metric	Q2 2026	Q1 2026	Q3 2025	Q2 2025	Q1 2025	Q3 2024	Q2 2024	Q1 2024	Q3 2023	Q2 2023	Q1 2023	Q3 2022	Q2 2022	Q1 2022	Q3 2021	Q2 2021	Q1 2021
Cash & Equivalents	179.73	40.75	72.89	52.91	66.11	36.63	33.27	63.91	45.56	81.39	88.33	85.34	151.41	131.64	57.59	121.56	156.59
Inventory	45.15	46.41	44.79	46.50	46.20	38.71	38.85	39.76	32.82	33.16	31.75	25.32	25.86	26.27	19.29	17.38	15.94
Total Current Assets	541.32	480.24	438.74	408.97	405.76	440.46	409.67	398.22	426.47	415.91	423.65	459.70	453.19	477.62	329.22	349.69	372.25
Property, Plant & Equipment	1.86	1.99	2.27	2.42	2.58	2.89	3.04	3.20	3.50	3.65	3.84	3.76	4.18	4.33	4.55	4.81	4.76
Intangible Assets	3.38	3.59	3.90	4.05	4.16	4.51	4.62	4.76	5.26	5.68	6.10	6.84	7.34	7.88	8.93	9.29	9.85
Total Non-current Assets*	250.94	243.75	88.79	93.59	99.09	108.90	113.86	118.41	128.54	132.99	28.11	28.59	28.96	29.28	30.85	36.58	44.83
Total Assets	792.26	724.00	527.53	502.56	504.85	549.36	523.53	516.63	555.01	548.90	451.76	488.29	482.15	506.90	360.07	386.27	417.08
Accounts Payable	64.11	58.20	49.54	49.70	42.35	56.77	56.46	50.27	52.31	41.38	35.97	40.12	32.38	32.33	29.97	25.83	17.69
Total Current Liabilities	99.89	86.56	76.22	78.27	68.41	78.61	76.90	71.05	73.89	61.66	42.05	41.77	34.63	33.84	37.54	29.32	21.15
Total Non-current Liabilities*	77.51	69.82	85.54	89.00	86.25	82.75	82.01	86.11	89.25	94.95	19.31	23.10	23.75	24.94	24.36	24.70	25.70
Total Liabilities	177.40	156.37	161.76	167.26	154.66	161.36	158.91	157.16	163.14	156.61	61.35	64.87	58.38	58.78	61.89	54.01	46.85
Retained Earnings	(577.60)	(615.01)	(860.16)	(891.71)	(913.23)	(938.00)	(952.35)	(953.07)	(915.45)	(902.00)	(890.51)	(838.26)	(829.27)	(793.75)	(722.80)	(672.54)	(625.53)
Total Stockholder Equity	614.86	567.63	365.77	335.30	350.19	388.00	364.62	359.48	391.88	392.29	390.41	423.43	423.77	448.12	298.17	332.26	370.23

* Derived from reported values

Income Statement

(in millions USD) (except per-share rows)

Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021
Total Revenue	83.22	77.71	77.11	73.47	70.01	62.47	59.87	67.77	57.19	50.30	45.10	54.52	41.49	34.41	28.44	55.78	28.19	21.63	23.40	14.67
Cost of Revenue	6.56	6.51	8.80	8.18	7.12	8.57	5.55	6.04	8.91	7.75	5.40	6.77	1.56	0.42	1.36	2.45	1.60	0.26	0.48	0.25
Gross Profit	76.67	71.20	68.32	65.29	62.89	53.89	54.32	61.74	48.28	42.55	39.70	47.75	39.93	33.99	27.07	53.33	26.59	21.37	22.92	14.41
Research & Development	13.05	7.47	10.90	8.44	7.43	5.74	8.11	3.05	4.08	5.55	10.23	13.61	12.65	13.16	9.87	10.97	11.53	12.62	11.15	20.07
Selling, General & Admin	23.51	22.03	29.26	26.18	26.02	20.34	37.03	42.37	44.93	47.70	50.07	47.76	47.08	50.12	47.47	52.17	51.53	45.20	44.24	44.13
Total Operating Expenses*	30.32	29.78	67.74	35.55	42.81	32.04	84.23	49.99	49.80	55.80	69.37	64.01	56.10	63.57	55.17	62.83	62.58	59.25	55.63	64.77
Operating Income	46.34	41.42	33.24	29.75	20.08	21.85	(1.67)	11.75	(1.51)	(13.25)	(29.67)	(16.26)	(16.17)	(29.58)	(28.10)	(9.50)	(35.99)	(37.88)	(32.70)	(50.35)
Interest Expense	--	--	--	--	--	--	--	--	1.20	1.28	1.31	1.40	0.07	--	--	--	--	--	--	--
Pretax Income	48.79	43.93	35.69	31.96	22.16	24.35	1.17	14.81	1.48	(10.01)	(26.42)	(13.15)	(12.13)	(25.77)	(25.19)	(8.03)	(35.51)	(37.62)	(32.60)	(50.25)
Tax Provision	11.37	9.57	(175.10)	0.41	0.64	1.00	(0.26)	0.46	0.76	0.74	0.46	0.30	(0.64)	0.44	0.86	0.95	0.01	0.01	0.73	0.01
Net Income	37.41	34.35	210.79	31.55	21.51	23.34	1.43	14.35	0.72	(10.75)	(26.87)	(13.45)	(11.49)	(26.21)	(26.05)	(8.99)	(35.51)	(37.63)	(33.32)	(50.25)
Basic EPS	0.29	0.26	1.57	0.24	0.16	0.17	0.00	0.10	0.01	(0.07)	(0.19)	(0.09)	(0.08)	(0.18)	(0.18)	(0.06)	(0.25)	(0.27)	(0.25)	(0.39)
Diluted EPS	0.28	0.25	1.52	0.23	0.16	0.16	0.00	0.10	0.01	(0.07)	(0.19)	(0.09)	(0.08)	(0.18)	(0.18)	(0.06)	(0.25)	(0.27)	(0.25)	(0.39)

* Derived from reported values

Cash Flow Statement

(in millions USD)

Metric	Q2 2026	Q1 2026	Q4 2025	Q3 2025	Q2 2025	Q1 2025	Q4 2024	Q3 2024	Q2 2024	Q1 2024	Q4 2023	Q3 2023	Q2 2023	Q1 2023	Q4 2022	Q3 2022	Q2 2022	Q1 2022	Q4 2021	Q3 2021
Operating Cash Flow	52.57	32.56	45.67	44.45	44.24	1.30	30.11	17.03	15.84	(18.60)	14.31	(13.28)	(2.83)	(31.67)	10.45	(15.36)	(27.87)	(46.75)	(25.92)	(40.25)
Capital Expenditures	0.00	0.04	0.07	0.07	0.10	0.02	0.28	0.00	0.00	0.00	0.30	(0.10)	0.18	0.35	0.13	0.04	0.04	0.08	0.04	(0.10)
Free Cash Flow*	52.57	32.52	45.60	44.38	44.14	1.28	29.83	17.03	15.84	(18.60)	14.01	(13.17)	(3.00)	(32.02)	10.32	(15.40)	(27.91)	(46.82)	(25.96)	(40.15)
Investing Cash Flow	81.45	(18.08)	(36.76)	(13.77)	(13.27)	31.03	39.22	(10.57)	(38.62)	49.23	(6.26)	(19.70)	(5.61)	24.86	(3.02)	(50.22)	45.62	(53.02)	(5.49)	(32.81)
Financing Cash Flow	4.81	(53.68)	(1.89)	(10.49)	(44.39)	(49.34)	(23.05)	(2.72)	(8.27)	(15.05)	(5.58)	(2.33)	1.14	1.64	0.69	0.00	1.34	0.41	205.72	9.08

* Derived from reported values